<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097560</url>
  </required_header>
  <id_info>
    <org_study_id>FAHGZ-20210811</org_study_id>
    <nct_id>NCT05097560</nct_id>
  </id_info>
  <brief_title>The Effect of HFNC on Exercise Capacity Compared to VM in COPD Patients Recovering From Acute Evacerbation</brief_title>
  <official_title>The Effect of High Flow Nasal Cannula on Exercise Capacity Compared to Venturi Mask in COPD Patients Recovering From Acute Evacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early PR is thought to be effective in COPD patients recovering from acute exacerbation,&#xD;
      while the effect of HFNC during exercise training in these patients remains unclear. The&#xD;
      study may provide evidence of early PR in COPD patients recovering from acute exacerbation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that HFNC may increases exercise time in COPD patients recovering from acute&#xD;
      exacerbation compare to VM. A randomized, cross-over clinical trial in which either HFNC or&#xD;
      VM may be used as an adjunct in 10-MST in random order, respectively, will be performed to&#xD;
      compare the endurance time. The physiological effect of HFNC and VM during exercise will also&#xD;
      be measured to explore the mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time</measure>
    <time_frame>10 minute</time_frame>
    <description>Endurance time for 10 minute steping test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory pattern</measure>
    <time_frame>10 minute</time_frame>
    <description>Respiratory pattern is calculated by the flow and time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work of breathing</measure>
    <time_frame>10 minute</time_frame>
    <description>Work of breathing is calculated by the transdiaphragmatic pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neural respiratory drive</measure>
    <time_frame>10 minute</time_frame>
    <description>Neural respiratory drive is calculated by diaphragm electromyogram</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>HFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Set FiO2 28%&#xD;
Titrate the flow of HFNC at the highest tolerated value up to 60 L/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- Keep FiO2 constant with VM and HFNC during the two trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high flow nasal cannula</intervention_name>
    <description>HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.</description>
    <arm_group_label>HFNC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venturi mask</intervention_name>
    <description>VM is commonly used by COPD patients during exercise training.</description>
    <arm_group_label>VM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hospitalized AECOPD patients&#xD;
&#xD;
          -  be ambulatory by 48h after admission for AECOPD&#xD;
&#xD;
          -  requires oxygen by screening exercise test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active coronary ischemia&#xD;
&#xD;
          -  respiratory diseases other than COPD&#xD;
&#xD;
          -  unstable vital signs&#xD;
&#xD;
          -  unstable psychological status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongchang Chen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiying Fang, MD</last_name>
    <phone>+8602083062882</phone>
    <email>fangshiying2019@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shiying</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiying Fang, MD</last_name>
      <phone>+8602083062882</phone>
      <email>fangshiying2019@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Rongchang Chen, PhD</last_name>
      <phone>+8613902273260</phone>
      <email>chenrc@vip.163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Shiying Fang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HFNC</keyword>
  <keyword>PR</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

